Synopsys Benefit from Receivables decreased by 70.0% to $8.21M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 17.3%, from $9.92M to $8.21M. Over 3 years (FY 2021 to FY 2025), Benefit from Receivables shows an upward trend with a 40.1% CAGR.
csco_benefit_from_receivables| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.57M | $3.76M | $4.70M | $5.28M | -$9.79M | $3.70M | $2.43M | $5.80M | $8.00M | $6.06M | $3.93M | $4.71M | $5.03M | $9.92M | $6.02M | $7.62M | $27.33M | $8.21M |
| QoQ Change | — | +46.2% | +25.0% | +12.3% | -285.6% | +137.8% | -34.2% | +138.4% | +37.8% | -24.2% | -35.2% | +19.9% | +6.8% | +97.3% | -39.3% | +26.5% | +258.7% | -70.0% |
| YoY Change | — | — | — | — | -480.5% | -29.9% | +124.9% | — | — | +63.8% | +61.4% | -18.9% | -37.1% | +63.7% | +53.3% | +61.8% | +443.6% | -17.3% |